EGFR and non-small cell lung carcinoma: Consistent with the report that the expression of α3β1 integrin was increased in erlotinib-resistant NSCLC tumors [49], we found that LXY30 was the most prevalent and potent integrin ligand for binding to live EGFR-mutant lung cancer.